ELI LILLY AND COMPANY |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 734.9 USD | +0.19% |
|
+0.31% | +25.85% |
| 03:11pm | Big tech saves the day, again |  |
| 07:21am | Habeck's 'pharma trip' - industry sees structural problems | DP |
Financials (USD)
| Sales 2024 * | 41.36B | Sales 2025 * | 51.28B | Capitalization | 661B |
|---|---|---|---|---|---|
| Net income 2024 * | 10.86B | Net income 2025 * | 15.78B | EV / Sales 2024 * | 16.3 x |
| Net Debt 2024 * | 15.19B | Net Debt 2025 * | 10.74B | EV / Sales 2025 * | 13.1 x |
| P/E ratio 2024 * |
60.5
x | P/E ratio 2025 * |
40.9
x | Employees | 43,000 |
| Yield 2024 * |
0.71% | Yield 2025 * |
0.81% | Free-Float | 99.79% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
| 1 day | +0.50% | ||
| 1 week | +0.54% | ||
| Current month | -5.49% | ||
| 1 month | -3.33% | ||
| 3 months | +13.99% | ||
| 6 months | +29.97% | ||
| Current year | +26.13% |
1 week
718.30
752.64
1 month
718.30787.90
Current year
579.05800.78
1 year
392.26800.78
3 years
181.19800.78
5 years
101.36800.78
10 years
57.81800.78
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 00-12-31 |
Ruth Gimeno
PSD | President | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 67 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 04-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.49% | 18 M€ | +3.79% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 733.6 | +0.01% | 1 039 600 |
| 24-04-26 | 733.5 | +1.19% | 2,009,249 |
| 24-04-25 | 724.9 | -1.00% | 2,608,752 |
| 24-04-24 | 732.2 | -1.81% | 2,133,427 |
| 24-04-23 | 745.7 | +1.96% | 2,042,029 |
Delayed Quote Nyse, April 29, 2024 at 09:55 am EDT
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
2024-04-30
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
733.5
USD
Average target price
813.3
USD
Spread / Average Target
+10.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.13% | 661B | |
| +26.89% | 566B | |
| -6.31% | 352B | |
| +20.60% | 332B | |
| +3.73% | 283B | |
| +14.23% | 231B | |
| +5.13% | 200B | |
| -8.96% | 195B | |
| -4.91% | 145B | |
| -10.80% | 144B |
- Stock Market
- Equities
- LLY Stock
